Novo Nordisk nach Split WKN: A3EU6F ISIN: DK0062498333 Kürzel: NOV Forum: Aktien User: Coronaprofiteur

43,86 EUR
+2,38 % +1,02
2. Juli 2026, 22:59 Uhr, L&S Exchange
Kommentare 53.375
P
Papadopoulos, Gestern 22:32 Uhr
0
Was die orale Lösungen angeht sind wir deutlich besser, bei der initiierten nicht unbedingt. Schade das Caprisegma nicht dieselbe efficacy wir zepboud hat. Caprisegma HD wird direkt mehr als zepbound können aber bis er raus kommt müssen wir mit der Pille aushalten Week 24 had a holiday – Juneteenth – with some pharmacies closed or at reduced opening hours. This meant almost all GLP1 saw negative growth in week 24 but with orals hit harder than injections. But this could also potentially give week 25 an extra boost. Wegovy pill + pen Down with 1.8% vs week 23 Wegovy brand share at 40.7%, down from 41.4% the week before If we include ALL online sales of wegovy pills (estimated 64.5% capture rate) then the implied market share is 44.6%. Down from 45.4% in week 23 Wegovy pill W24 TRx dropped by 5.9% vs the week before that saw record level. For week 24 Wegovy pill had 32.6% of all reported wegovy brand scripts (pill + pen) Down from 34% the week before. Wegovy pill has 13.3% of total obesity market in US. (reported numbers) Down from 14.1% in week 23. If all online sales were reported, wegovy pill would have about 42.5% share of all wegovy scripts. Down from 44% in week 23. Marked with red – if all online sales were reported, Wegovy pill would have 19% market share of total obesity market. Down 1.2% vs the week before. NVO survey of Medicare Bridge seniors showed that 75% of all surveyed had preference for how to dose. 25% want an injection but 50% go for a pill. The last 25% had no specific preference. This might look like oral will take the main share. That would be very positive for NVO since they are currently outselling Foundayo 10:1. That’s not to say this will translate 1:1 in the Bridge program. But I have yet to see any analyst forecasting Foundayo will take the lion share of oral in the Bridge program. There have been speculations that the price for 4mg will increase from $149 to $199. NVO has confirmed the price will stay at $149 Εικόνα Wegovy pen Wegovy pen increased 0.3% in week 24 vs week 23. Wegovy HD keeps increasing. Up more than 5% in week 24. Theres very little focus on Wegovy HD performance. But this is the main driver behind the new growth period for wegovy pen. It has reduced the number of people moving from Wegovy 2.4mg to Zepbound for higher efficacy. Wegovy HD gives about 3% higher WL than Wegovy 2.4 This week we learned that about 30% of all wegovy pen consumers are paying cash. They think they can increase that to about 50% over time. Zepbound Zepbound had a very strong week despite a holiday. Up with 1.4% vs week 23. Very strong KwikPen still keeps increasing week by week. Converting users from vials. It’s also a significant improvement in usability over vials Zepbound market share increased to 57.5% by 0.8 percentage points from week 23. I expect to see Zepbound perform greatly in Bridge program that just started yesterday. Many seniors that’s already lined up. Foundayo Week 9 Foundayo saw a drop of 4.9% vs week 23 Still no visible effect yet from their first TV advertisement campaign that’s has been running through week 23 and week 24. But I still expect to see Foundayo getting a substantial boost from Bridge program. Foundayo keeps doing significantly better in IQVIA vs Symphony. Much larger difference than wegovy pill split between IQVIA and Symphony. So Foundayo is likely seeing a higher share through online sales than wegovy pill. Foundayo now has 1.8% market share in obesity. Down 0.1 percentage points from week 23 Mounjaro/Ozempic Mounjaro was flat in week 24 and Ozempic was down by 0.5%. Mounjaro market shares up by 0.2 percentage point to 53.9%. Ozempic market share dropped 0.1 percentage point to 34.5% The last 13 weeks saw Mounjaro scripts increase with 9% vs Ozempic down 1% during that same 13-week period NVO desperately needs a more powerful T2D molecule
McLovin09
McLovin09, Gestern 23:01 Uhr
1

Was die orale Lösungen angeht sind wir deutlich besser, bei der initiierten nicht unbedingt. Schade das Caprisegma nicht dieselbe efficacy wir zepboud hat. Caprisegma HD wird direkt mehr als zepbound können aber bis er raus kommt müssen wir mit der Pille aushalten Week 24 had a holiday – Juneteenth – with some pharmacies closed or at reduced opening hours. This meant almost all GLP1 saw negative growth in week 24 but with orals hit harder than injections. But this could also potentially give week 25 an extra boost. Wegovy pill + pen Down with 1.8% vs week 23 Wegovy brand share at 40.7%, down from 41.4% the week before If we include ALL online sales of wegovy pills (estimated 64.5% capture rate) then the implied market share is 44.6%. Down from 45.4% in week 23 Wegovy pill W24 TRx dropped by 5.9% vs the week before that saw record level. For week 24 Wegovy pill had 32.6% of all reported wegovy brand scripts (pill + pen) Down from 34% the week before. Wegovy pill has 13.3% of total obesity market in US. (reported numbers) Down from 14.1% in week 23. If all online sales were reported, wegovy pill would have about 42.5% share of all wegovy scripts. Down from 44% in week 23. Marked with red – if all online sales were reported, Wegovy pill would have 19% market share of total obesity market. Down 1.2% vs the week before. NVO survey of Medicare Bridge seniors showed that 75% of all surveyed had preference for how to dose. 25% want an injection but 50% go for a pill. The last 25% had no specific preference. This might look like oral will take the main share. That would be very positive for NVO since they are currently outselling Foundayo 10:1. That’s not to say this will translate 1:1 in the Bridge program. But I have yet to see any analyst forecasting Foundayo will take the lion share of oral in the Bridge program. There have been speculations that the price for 4mg will increase from $149 to $199. NVO has confirmed the price will stay at $149 Εικόνα Wegovy pen Wegovy pen increased 0.3% in week 24 vs week 23. Wegovy HD keeps increasing. Up more than 5% in week 24. Theres very little focus on Wegovy HD performance. But this is the main driver behind the new growth period for wegovy pen. It has reduced the number of people moving from Wegovy 2.4mg to Zepbound for higher efficacy. Wegovy HD gives about 3% higher WL than Wegovy 2.4 This week we learned that about 30% of all wegovy pen consumers are paying cash. They think they can increase that to about 50% over time. Zepbound Zepbound had a very strong week despite a holiday. Up with 1.4% vs week 23. Very strong KwikPen still keeps increasing week by week. Converting users from vials. It’s also a significant improvement in usability over vials Zepbound market share increased to 57.5% by 0.8 percentage points from week 23. I expect to see Zepbound perform greatly in Bridge program that just started yesterday. Many seniors that’s already lined up. Foundayo Week 9 Foundayo saw a drop of 4.9% vs week 23 Still no visible effect yet from their first TV advertisement campaign that’s has been running through week 23 and week 24. But I still expect to see Foundayo getting a substantial boost from Bridge program. Foundayo keeps doing significantly better in IQVIA vs Symphony. Much larger difference than wegovy pill split between IQVIA and Symphony. So Foundayo is likely seeing a higher share through online sales than wegovy pill. Foundayo now has 1.8% market share in obesity. Down 0.1 percentage points from week 23 Mounjaro/Ozempic Mounjaro was flat in week 24 and Ozempic was down by 0.5%. Mounjaro market shares up by 0.2 percentage point to 53.9%. Ozempic market share dropped 0.1 percentage point to 34.5% The last 13 weeks saw Mounjaro scripts increase with 9% vs Ozempic down 1% during that same 13-week period NVO desperately needs a more powerful T2D molecule

Cagrisema wird auf dem Label den höchsten Gewichtsverlust aller zugelassenen Medikamenten stehen haben, mehr als Zepbound! REDEFINE-4 war ein riesen Fehler von Novo. Durch die flexible Titration sind zu viele in der Studie nicht bis zur höchsten Dosis gegangen was ganz einfach das Potential beschnitten hat. Dazu kommt, es war open Label, die leute wussten das sie Zepbound bekommen haben was zu einem höheren Wert geführt hat als Lilly in ihrer eigenen Studie nachweisen konnte. In REDEFINE-11 ist die Titration fest vorgeschrieben, hoffentlich ist dadurch das volle Potenzial zu sehen.
McLovin09
McLovin09, Gestern 21:45 Uhr
0
So mal schauen wie die Amis ihre woche beenden. Morgen bleibt dort die Börse zu
McLovin09
McLovin09, Gestern 21:16 Uhr
1

Warum steigt aber Eli Lilly so krass mit, wenn die Pille sich eigentlich gar nicht verkauft?

Tirzepatide hatte letzte woche eine rekordwoche. Lilly ist nicjt von foundayo abhängig. Der ganze Markt wächst enorm
G
GLP1Lover, Gestern 20:58 Uhr
0
Warum steigt aber Eli Lilly so krass mit, wenn die Pille sich eigentlich gar nicht verkauft?
McLovin09
McLovin09, Gestern 20:38 Uhr
1
https://www.thesun.co.uk/health/39625790/wegovy-pill-superdrug-launches-weight-loss-tablet/?utm_term=Autofeed&utm_medium=Social&utm_source=Twitter#Echobox=1783009598 Wegovy pille in uk ab heute erhältlich mal gucken ob andere Apotheken nachziehen
csl1234
csl1234, Gestern 20:28 Uhr
0

Anschnallen die Fahrt geht los

Morgan Stanley wird eine leichte Korrektur des eigenen Modells durchführen müssen ... 🤡
hodler01
hodler01, Gestern 20:20 Uhr
0
😎🫡 Jawohl Kollege
McLovin09
McLovin09, Gestern 20:20 Uhr
2
Anschnallen die Fahrt geht los
McLovin09
McLovin09, Gestern 20:19 Uhr
0
Wegovy pille verkauft sich mit dem Faktor 10!
McLovin09
McLovin09, Gestern 20:18 Uhr
0
Fragezeichen drücken, um Tastatur Kurzbefehle anzuzeigen Tastatur Kurzbefehle anzeigen Wegovy pill outsells Foundayo 10.3X....... ResearchPulse @ResearchPulse1 · 33 Min. Last week $LLY told analysts that capture rate for Foundayo is 90%. That means IQVIA captures 90% of total Foundayo sales. With last week’s IQVIA data being TRx 20,593, that means the true total Foundayo scripts was about 22,900 Now compare that with IQVIA numbers for Wegovy pill that were 151,963 last week. $NVO has guided that capture rate is between 60-65%. In my model I use 64.5% That means the true total wegovy pill scripts for last week were about 235.500. That means Wegovy pill currently outsells Foundayo 10.3x……! That’s a lot larger difference than what any analysts had thought. Morgan Stanley has since the launch of Foundayo said they expect Foundayo to catch wegovy pill sales numbers after 16 weeks, so that they would have 50/50 market. That was still their model after the first 11 weeks of Foundayo sales. This clearly shows the actual strength of Wegovy pill launch. And, many analysts, especially those covering LLY but not NVO have a long way to go for adapting to reality. I still see Foundayo becoming a very successful multi-Billion-dollar drug. But in markets where wegovy pill is launched, Foundayo will get a smaller market share. However, in diabetes, I see huge potential. That is If we don’t start to see too many consumers experience increased liver enzyme signal. This is a latent risk for Foundayo. Medicare Bridge just started yesterday. That will boost all 4 obesity meds. But some surveys seem to point towards oral is more preferred over injections in Medicare population. Both Foundayo and Wegovy pill would benefit from that, although Wegovy pill likely taking the largest share of oral scripts
T
Tetze, Gestern 19:13 Uhr
0
40% hoch in der kurzen Zeit, ist schon stark. Trotzdem darf man nicht vergessen, eine Kackmeldung und wieder 20% runter, dann sind die 40% fast komplett weg. Hatte deshalb auch einiges verkauft, den Rst behalte ich hoffe erstmal auf 50+
McLovin09
McLovin09, Gestern 18:53 Uhr
0
Sehr gutes Zeichen das es weiter hoch geht
McLovin09
McLovin09, Gestern 18:53 Uhr
0
Despite recovering around 40% from its March lows, $NVO was the most sold stock among Danish retail investors on Nordnet in June. Nordnet called the development "surprising," noting that several analysts have recently speculated Novo Nordisk could raise its 2026 guidance following the strong launch of Oral Wegovy. Nevertheless, many retail investors chose to take profits during the month. Link: euroinvestor.dk/nyheder/overra… #StocksInFocus #Investing
T
Trader_with_passion, Gestern 18:17 Uhr
0

Ob ich meine 70€ jemals sehen werde?☺️🥰

Ja, das kann schnell gehen. Ich persönlich hoffe, dass dieses Anfang 2027 möglich ist. Mein EK ist 46 €. Mein Ziel ist eine Verdopplung bis 2028.
Mehr zu diesem Wert
Thema
1 Novo Nordisk nach Split
2 Novo Nordisk
Meistdiskutiert
Thema
1 BAYER Hauptdiskussion +8,62 %
2 ALPHABET Hauptdiskussion -0,55 %
3 Keel Infrastructure Corporation Hauptdiskussion -14,50 %
4 DeFi Technologies: Eine Perle? +4,05 %
5 NEL ASA Hauptdiskussion -0,95 %
6 für alle, die es ehrlich meinen beim Traden.
7 AIXTRON Hauptdiskussion -12,27 %
8 REALTY INCOME Hauptdiskussion +2,89 %
9 RHEINMETALL Hauptdiskussion +12,92 %
10 ZALANDO Hauptdiskussion +4,26 %
Alle Diskussionen
Aktien
Thema
1 BAYER Hauptdiskussion +8,62 %
2 ALPHABET Hauptdiskussion -0,55 %
3 Keel Infrastructure Corporation Hauptdiskussion -14,50 %
4 DeFi Technologies: Eine Perle? +4,05 %
5 NEL ASA Hauptdiskussion -0,95 %
6 AIXTRON Hauptdiskussion -12,27 %
7 REALTY INCOME Hauptdiskussion +2,89 %
8 RHEINMETALL Hauptdiskussion +12,92 %
9 ZALANDO Hauptdiskussion +4,26 %
10 BALLARD POWER Hauptdiskussion -7,35 %
Alle Diskussionen